High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma
about
Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinomaOptimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directionsProgress in molecular-based management of differentiated thyroid cancerPrognostic value of the BRAF V600E mutation in papillary thyroid carcinoma2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerGenetic and epigenetic alterations in differentiated thyroid carcinoma.Applying new clinicopathological characteristics to prognostication in advanced thyroid carcinoma.Prognostic utility of BRAF mutation in papillary thyroid cancer.New insights in risk stratification of differentiated thyroid cancer.Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivoMolecular pathogenesis and mechanisms of thyroid cancerBRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patientsBRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancerDevelopment and characterization of six new human papillary thyroid carcinoma cell lines.Diagnosis and treatment of patients with thyroid cancer.Clinical and molecular features of papillary thyroid cancer in adolescents and young adultsAssociation of TERT Promoter Mutation, But Not BRAF Mutation, With Increased Mortality in PTC.Contactin 1 as a potential biomarker promotes cell proliferation and invasion in thyroid cancerB-Raf mutation and papillary thyroid carcinoma patients.Identification of Differentially Expressed Kinase and Screening Potential Anticancer Drugs in Papillary Thyroid Carcinoma.Xenograft models of head and neck cancers.Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study.Diagnostic markers and prognostic factors in thyroid cancer.Iodine mediated mechanisms and thyroid carcinoma.Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines.Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer.Personalization of targeted therapy in advanced thyroid cancer.Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.Emerging role of multikinase inhibitors for refractory thyroid cancer.BRAFV600E mutation and papillary thyroid cancer: chicken or egg?Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.Correlation between polymorphisms of BRAF gene and papillary thyroid carcinoma.Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma.The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer CellsScreening of pharmacogenetic variants associated with drug sensitivity in patients with papillary thyroid carcinoma using next generation sequencingBRAF V600E and RET/PTC Promote the Activity of Nuclear Factor-κB, Inflammatory Mediators, and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Study of 50 Patients in Inner Mongolia
P2860
Q24616408-13CE4B45-473A-42C6-B725-88F7A95EB79AQ26863326-AF856327-C975-4C16-A92A-2E6050503464Q26999887-AA954AA4-C62E-4233-8DDC-282B46A1ACD0Q27852780-848B802A-F595-447E-8B56-B22D87C9F33AQ30367068-719317A0-AF2C-4062-A196-9EA01DE3F5B0Q33665984-3C7FCE38-FB2B-47CF-B141-FB2091C27668Q33687963-382234E5-962A-4D48-ADC9-1AC07D898B66Q33771120-52DF9B4F-BEB4-48B2-965B-AD31C81D6FB6Q33915384-98AC0184-8477-4DA0-AFC0-911F8838A415Q33931450-2CFF241F-A498-4E4F-90B9-B92E87C8A01BQ34109756-33457A49-E4CE-4AB1-A90E-59C589050C1EQ34329018-E4E9B1D2-F3F1-4BBC-A9C5-9A046BF1766BQ34637861-B0197489-CA9C-40F6-86F2-2FBB62CF608DQ34919430-F345CCEC-122E-47D4-A76E-D5ACEB7CBF69Q35055107-F54DBE46-35E6-4A82-8C87-B83837D9B0ABQ35555583-805A9102-BC66-4271-BA97-19DD46165BCBQ36293091-648E5661-124C-429D-81AA-CC8457C62DDCQ36339926-EE372E80-B0A6-4B85-9329-C5AA25F4ACC9Q36375125-EDE49E91-6865-42C7-9116-1A2FA79E65F6Q36741221-56AFF2DA-6BC7-4F89-8EE0-9EAC9BEB5270Q37293444-F3425364-7EF9-40FC-8A3A-FDF2FA515E9CQ37332682-65C50D1D-72A0-45A1-B63E-53288F832E5FQ37562646-F61818DD-380F-4FFE-BBDD-D88A16AF9E61Q37620399-47C5B615-E5FF-4B0F-9DB7-AEEADF3C64D9Q37643737-2532BEFA-0B8B-4136-BD10-9A67A813C14DQ37667684-11560516-488A-4245-A457-69854A15FA70Q37767709-7931F632-2915-4DF2-8D07-5D0CA6A60111Q38823954-64114211-32F2-4E9C-8F86-2687CF8E1F03Q39006509-E12269B8-7C4B-4EF5-9438-C306EF8FD6ADQ39040663-98D10FD2-C0D2-4B45-94F8-C1531716F7A1Q40922523-02043ADE-6CDF-4E9D-AD9C-96BE9706A4E5Q41418283-F917EB54-8D6E-42D5-8BA1-4F859AF592A0Q41837594-366FA454-7C4C-4774-A38A-A02331C5548AQ42707282-44944119-7208-4BE1-899F-3AD22ECC5B83Q53352497-49AC5F71-3E2B-416F-AC5D-55DD4D2376B5Q54164764-005E0B44-8337-4614-B9C9-3138B1FE055AQ54967888-D5A73CD8-4436-4446-B228-9EAB01B9F39DQ57150715-26805006-1B67-4B94-A1F8-BE07416FC593Q58050534-D6AA2000-3CB0-4471-95CA-38A90FA92F3CQ58693775-AA40CB57-7E4B-4BAA-8B96-1845280F7753
P2860
High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma
@ast
High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma
@en
High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma
@nl
type
label
High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma
@ast
High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma
@en
High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma
@nl
prefLabel
High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma
@ast
High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma
@en
High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma
@nl
P2093
P2860
P1476
High rate of BRAF and RET/PTC ...... nt papillary thyroid carcinoma
@en
P2093
Adel K El-Naggar
Gary L Clayman
Kathleen M Cieply
Mitchell J Fredrick
Thomas D Shellenberger
Ying C Henderson
P2860
P304
P356
10.1158/1078-0432.CCR-08-0933
P407
P577
2009-01-01T00:00:00Z